Moyer C, Allen D, Basabe A, Maronpot R R, Nyska A
Pathology Associates--A Charles River Company, Raleigh, North Carolina, USA.
Exp Toxicol Pathol. 2004 Jul;55(6):455-65. doi: 10.1078/0940-2993-00344.
Riddelliine alters hepatocellular and endothelial cell kinetics and function including stimulating an increase in hepatocytic vascular endothelial growth factor (VEGF) in the absence of increased serological levels of VEGF (NYSKA et al. 2002). The objective of this study was to further assess hepatic VEGF and KDR/flk-1 synthesis and expression by hepatic cells under riddelliine treatment conditions. Forty-two male F344/N rats were dosed by gavage with riddelliine (0, 1.0, and 2.5 mg/kg/day) for 6 weeks. Seven animals/group were sacrificed after 8 consecutive daily doses; remaining rats were terminated after 30 daily doses, excluding weekends. Hepatic tissues were evaluated by immunohistochemistry and in situ hybridization. The results showed that VEGF mRNA expression was observed in control and treated animals; however, qualitative differences were noted. Treated animals exhibited VEGF mRNA in clustered, focal hepatocytes and bile duct epithelium, whereas VEGF mRNA in hepatocytes from vehicle control rats was distributed evenly across all hepatocytes. Results evaluating the distribution of the VEGF cognate receptor, KDR/flk-1 showed that randomly distributed, rare sinusoidal endothelium, including those demonstrating karyomegaly and cytomegaly expressed KDR/flk-1. Phosphorylation of KDR/flk-1 at pTyr996 and pTyr1054/1059, but not pTyr951, was also detected, evidence that endothelial cell KDR/flk-1 was activated. These results suggest that both hepatocytes and endothelial cells are targets of riddelliine-induced injury. We speculate that damage to both populations of cells may lead to dysregulated VEGF synthesis by hepatocytes and activation of KDR/flk-1 by endothelium leading to the induction of sustained endothelial cell proliferation, culminating in the development of hepatic hemangiosarcoma.
瑞得灵(riddelliine)可改变肝细胞和内皮细胞的动力学及功能,包括在血清血管内皮生长因子(VEGF)水平未升高的情况下刺激肝细胞血管内皮生长因子(VEGF)增加(Nyska等人,2002年)。本研究的目的是进一步评估在瑞得灵处理条件下肝细胞中肝VEGF和KDR/flk-1的合成及表达情况。42只雄性F344/N大鼠通过灌胃给予瑞得灵(0、1.0和2.5毫克/千克/天),持续6周。每组7只动物在连续每日给药8次后处死;其余大鼠在30次每日给药后处死,周末除外。通过免疫组织化学和原位杂交对肝组织进行评估。结果显示,在对照动物和处理动物中均观察到VEGF mRNA表达;然而,注意到了定性差异。处理组动物的VEGF mRNA在成簇的、局灶性的肝细胞和胆管上皮中表达,而来自溶剂对照组大鼠的肝细胞中的VEGF mRNA则均匀分布于所有肝细胞中。评估VEGF同源受体KDR/flk-1分布的结果显示,随机分布的、罕见的肝血窦内皮细胞,包括那些显示核肿大和细胞肿大的内皮细胞表达KDR/flk-1。还检测到KDR/flk-1在pTyr996和pTyr1054/1059处的磷酸化,但未检测到pTyr951处的磷酸化,这证明内皮细胞KDR/flk-1被激活。这些结果表明,肝细胞和内皮细胞都是瑞得灵诱导损伤的靶点。我们推测,这两种细胞群体的损伤可能导致肝细胞VEGF合成失调以及内皮细胞激活KDR/flk-1,从而导致持续的内皮细胞增殖,最终发展为肝血管肉瘤。